Hot Melt Extrusion Solid Dispersion for Low Solubility Drugs

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Compounds with low aqueous and oil solubility, such as NK-1 receptor antagonists, face bioavailability issues due to insolubility and adverse interactions with food, leading to reduced effectiveness and potential adverse reactions when taken orally.

Innovation Solution

The development of galenic compositions for oral administration using hot melt extrusion of active pharmaceutical ingredients with a poloxamer, specifically a water-soluble poloxamer like Lutrol F68, to create a hot melt extrudate that enhances solubility and bioavailability, overcoming insolubility in simulated intestinal fluid.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If compounds with low aqueous and oil solubility are administered orally, then the drug can be delivered to patients, but the bioavailability is insufficient due to insolubility

Engineering Contradiction:
ImprovebioavailabilityVSAvoidaqueous solubility
Core Design Contradiction:
ReliabilityVSQuantity of substance

Solution Approach 1:

The patent changes the physical state of the drug from crystalline to amorphous form through hot melt extrusion processing. This parameter change in molecular arrangement and physical state dramatically increases aqueous solubility and bioavailability without altering the chemical structure of the NK-1 receptor antagonist

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite material system by combining the NK-1 receptor antagonist with a hydrophilic carrier polymer (such as polyethylene glycol or poloxamer) through hot melt extrusion. This composite approach enhances the solubility of the hydrophobic drug while maintaining its pharmacological activity

Inventive Principle:
Principle #40Composite materials

2Reliability

If drugs are taken with food, then absorption may be enhanced, but adverse interactions occur that diminish drug effectiveness

Engineering Contradiction:
Improvedrug effectivenessVSAvoidfood-drug interactions
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by pre-formulating the drug in an optimized delivery system (hot melt extrudate with hydrophilic carrier) before administration. This pre-processing of the drug substance ensures rapid dissolution and absorption independent of food presence, preventing food-drug interactions from occurring

Inventive Principle:
Principle #10Preliminary action

3Reliability

If vitamin and herbal supplements are taken with prescribed medication, then comprehensive treatment is provided, but adverse reactions occur

Engineering Contradiction:
Improvetreatment effectivenessVSAvoidadverse reactions
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent uses preliminary action by optimizing the drug's physical formulation beforehand through hot melt extrusion. This creates a highly soluble, rapidly dissolving dosage form that achieves therapeutic效果 quickly and predictably, reducing the window for potential interactions with supplements and minimizing adverse reactions

Inventive Principle:
Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The approach enables sufficient availability of the active compound at the site of action, improving oral bioavailability and reducing adverse interactions by forming a microcrystalline solid dispersion with improved dissolution characteristics.

Implementation Method 1

the compositions and process employ a hot melt extrusion of the active pharmaceutical ingredient and a poloxamer

Methodology Applied
Scientific EffectHot melt extrusion:

Implementation Method 2

forming a microcrystalline solid dispersion with improved dissolution characteristics

Methodology Applied
Scientific EffectSolid dispersion:

Implementation Method 3

a water-soluble poloxamer like Lutrol F68, to create a hot melt extrudate that enhances solubility and bioavailability

Methodology Applied
Scientific EffectSolubility enhancement:

Data Source

PatentUS8852634B2Dosage formulation
Publication Date: 2014.10.07 F HOFFMANN LA ROCHE INC

AI summary

The invention relates to a process for preparing a pharmaceutical tablet composition which comprises an active pharmaceutical ingredient of formula Iwherein the definitions are described in claim 1, or pharmaceutically acceptable acid addition salts thereof and a water soluble poloxamer in which the compound of formula I and the water soluble poloxamer are processed by hot melt extrusion, and then the hot melt extrudate is mixed with other ingredients to form a tablet, that is optionally coated with a composition comprising an immediate release film coating system and purified water. The invention also relates to such pharmaceutical compositions and hot melt extrudates.